Metabolic Surgery Shows Superior Renoprotective Effects in CKD Patients

Metabolic surgery significantly reduces kidney impairment progression and lowers the risk of kidney failure or death by 60% and 44%, respectively, when compared to GLP-1 receptor agonists in patients with type 2 diabetes, obesity, and established chronic kidney disease. This highlights the potential of metabolic surgery as a therapeutic option for individuals with CKD and obesity, offering superior renoprotective effects over GLP-1 receptor agonists.